Cargando…

Treatment of metastatic squamous cell carcinoma arising in sacrococcygeal pilonidal sinus: a case report series

BACKGROUND: Squamous cell carcinoma (SCC) arising in a sacrococcygeal pilonidal sinus is rare, with cases of metastatic disease being even rarer. Among published cases, almost none have reported on systemic treatment. OBJECTIVE: This disease has a poorer prognosis than other forms of cutaneous SCC;...

Descripción completa

Detalles Bibliográficos
Autores principales: Soria Rivas, Ainara, Bea-Ardebol, Sonia, Vida Navas, Elena, Muñoz-Arrones, Óscar M., Cabañas-Montero, Luis Jacobo, Mena-Mateos, Antonio, López-Campos, Fernando, Corral Moreno, Sara, Pérez-Muñoz, Israel, González Lizan, Fausto, Sanz Pascual, María, Serrano Domingo, Juan Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534040/
https://www.ncbi.nlm.nih.gov/pubmed/37780565
http://dx.doi.org/10.3389/fmed.2023.1248894
Descripción
Sumario:BACKGROUND: Squamous cell carcinoma (SCC) arising in a sacrococcygeal pilonidal sinus is rare, with cases of metastatic disease being even rarer. Among published cases, almost none have reported on systemic treatment. OBJECTIVE: This disease has a poorer prognosis than other forms of cutaneous SCC; therefore, our objective is to shed some light on the treatment of metastatic disease. METHODS: We present a series of nine cases treated at a single center, four of whom received systemic treatment. Additionally, other previously reported cases of metastatic disease are included in an attempt to draw stronger conclusions. RESULTS: Four patients were treated under several treatment regimens, with a median progression-free survival of only 2 months and two instances of partial response (18%). The best result was achieved with cemiplimab. Across all the cases, there was a trend toward a benefit of the use of systemic treatment (HR 0.41, 95% CI 0.15–1.12, p = 0.083; median overall survival 13 vs. 8 months). LIMITATIONS: Limitations include the significant lack of information on previously published cases and the extremely heterogeneous nature of the existing information. CONCLUSION: The initial systemic treatment should be an anti-PD-1, as with other SCCs. After progression on anti-PD-1, there is no strong evidence to support the recommendation of a specific treatment or sequence: options include cetuximab and/or chemotherapy (platinum, paclitaxel, 5-fluorouracyl).